© The Canadian Journal of Urology™; 21(Supplement 2); June 2014
11
A practical primary care approach to overactive bladder
27. Djavan B, Chapple C, Milani S et al. State of the art on the
efficacy and tolerability of alpha1-adrenoceptor antagonists
in patients with lower urinary tract symptoms suggestive of
benign prostatic hyperplasia.
Urology
2004;64(6):1081-1088.
28. Chang DF, Campbell JR. Intraoperative floppy iris syndrome
associated with tamsulosin.
J Cataract Refract Surg
2005;31(4):
664-673.
29. Roehrborn CG, McVary KT, Elion-Mboussa A et al. Tadalafil
administered once daily for lower urinary tract symptoms
secondary to benign prostatic hyperplasia: a dose finding study.
J Urol
2008;180(4):1228-1234.
30. Mulhall JP, Guhring P, Parker M et al. Assessment of the impact
of sildenafil citrate on lower urinary tract symptoms in men
with erectile dysfunction.
J Sex Med
2006;3(4):662-667.
31. McVary K, MonnigW, Camps JJ et al. Sildenafil citrate improves
erectile function and urinary symptoms in men with erectile
dysfunction and lower urinary tract symptoms associated with
benign prostatic hyperplasia: a randomized, doubleblind trial.
J Urol
2007;177(3):1071-1077.
32. Stief C, Porst H, Neuser D et al. A randomised, placebo-
controlled study to assess the efficacy of twice-daily vardenafil
in the treatment of lower urinary tract symptoms secondary to
benign prostatic hyperplasia.
Eur Urol
2008;53(6):1236-1244.
33. Gacci M, Vittori G, Tosi N et al. Arandomized, placebo-controlled
study to assess safety and efficacy of vardenafil 10 mg and
tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alonein the treatment
of lower urinary tract symptoms secondary to benign prostatic
hyperplasia.
J Sex Med
2012;9(6):1624-1633.
34. Ückert S, Oelke M, Stief CG et al. Immunohistochemical
distribution of cAMP- and cGMP-phosphodiesterase (PDE)
isoenzymes in the human prostate.
Eur Urol
2006;49(4):740-745.
35. Oelke M, Giulano F, Mirone V et al. Monotherapy with tadalafil
or tamsulosin similarly improved lower urinary tract symptoms
suggestive of benign prostatic hyperplasia in an international,
randomized, parallel, placebo-controlled clinical trial.
Eur Urol
2012;61(5):917-925.
36. Montorsi F, VerheydenB,MeulemanE et al. Long-termsafety and
tolerability of tadalafil in the treatment of erectile dysfunction.
Eur Urol
2004;45(3):339-344; Discussion 344-345.
37. Porst H, Rajfer J, CasabéAet al. Long-term safety and efficacy of
tadalafil 5mg dosed once daily inmenwith erectile dysfunction.
J Sex Med
2008;5(9):2160-2169.
38. NehraA, Jackson G, Miner M et al. The Princeton III Consensus
recommendations for the management of erectile dysfunction
and cardiovascular disease.
Mayo Clin Proc
2012;87(8):766-778.
39. Gittens PR, Lallas CD, Pe ML et al. Uropharmacology for the
primary care physician.
Can J Urol
2008;15(Suppl 1):78-91.
40. Rittmaster RS, Norman RW, Thomas LN et al. Evidence for
atrophy and apoptosis in the prostates of men given finasteride.
J Clin Endocrinol Metab
1996;81(2):814-819.
41. NaslundMJ, MinerM.Areviewof the clinical efficacy and safety
of 5a-reductase inhibitors for the enlarged prostate.
Clin Ther
2007;29(1):17-25.
42. Roehborn C, Siami P, Barkin J et al. The effects of combination
therapy with dutasteride and tamsulosin on clinical outcomes
in men with symptomatic benign prostatic hyperplasia: 4-year
results from the combat study.
Eur Urol
2010;57(1):123-131.
43. Kaplan SA, Roehrborn CG, McConnel JD et al. Long-term
treatment with finasteride results in a clinically significant
reduction in total prostate volume compared to placebo over
the full range of baseline prostate sizes in men enrolled in the
MTOPS trial.
J Urol
2008;180(3):1030-1032.
44. Morlock R, Goodwin B, Gomez Rey G et al. Clinical progression,
acute urinary retention, prostate-related surgeries, and costs in
patients with benign prostatic hyperplasia taking early versus
delayed combination 5
α
-reductase inhibitor therapy and
α
-blocker therapy: a retrospective analysis.
Clin Ther
2013;35(5):
624-633.
45. Kaplan SA. Editorial comment on: effect of discontinuation of
5alpha-reductase inhibitors on prostate volume and symptoms
in men with BPH: a prospective study.
Urology
2009;73(4):
2417.
46. AndrioleG, BruchovskyN, ChungLWet al. Dihydrotestosterone
and the prostate: the scientific rational for 5-alpha reductase
inhibitors in the treatment of benign prostatic hyperplasia.
J Urol
2004;172(4 Pt 1):1399-1403.
47. Thompson IM, Goodman PJ, Tangen CM et al. The influence of
finasteride on the development of prostate cancer.
N Engl J Med
2003;349(3):215-224.
48. DeCastro J, Stone B. Improving therapeutic outcomes in BPH
through diagnosis, treatment and patient compliance.
Am J Med
2008;121(8 Suppl 2):S27-S33.
